IDEXX Laboratories (IDXX) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.

7 equities research analysts have issued 12-month price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $600.00. On average, they expect the company's stock price to reach $527.86 in the next twelve months. This suggests a possible upside of 16.5% from the stock's current price.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.

IDEXX Laboratories' stock was trading at $407.96 on January 1st, 2023. Since then, IDXX stock has increased by 11.0% and is now trading at $453.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our IDXX earnings forecast.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings results on Monday, February, 6th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.13. The company had revenue of $828.60 million for the quarter, compared to analysts' expectations of $820.91 million. IDEXX Laboratories had a net margin of 20.38% and a trailing twelve-month return on equity of 117.37%. The firm's revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.89 EPS.
Read the conference call transcript.

ETFs with the largest weight of IDEXX Laboratories (NASDAQ:IDXX) stock in their portfolio include ProShares Pet Care ETF (PAWZ), Sterling Capital Focus Equity ETF (LCG), First Trust Water ETF (FIW), Invesco DWA Healthcare Momentum ETF (PTH), Neuberger Berman Disrupters ETF (NBDS), iShares U.S. Medical Devices ETF (IHI), Simplify Health Care ETF (PINK) and QRAFT AI-Enhanced U.S. Large Cap ETF (QRFT).

IDEXX Laboratories issued an update on its FY23 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $9.33-$9.75 for the period, compared to the consensus estimate of $9.63. The company issued revenue guidance of $3.619-$3.70 billion, compared to the consensus revenue estimate of $3.66 billion.

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.49%), State Street Corp (4.43%), Geode Capital Management LLC (2.35%), Franklin Resources Inc. (1.63%), Blair William & Co. IL (1.46%) and Brown Advisory Inc. (1.38%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDXX stock can currently be purchased for approximately $453.00.

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $37.55 billion and generates $3.37 billion in revenue each year. The company earns $679.09 million in net income (profit) each year or $8.31 on an earnings per share basis.

The company employs 10,780 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.